Tong Ren Tang secures Canadian product license for Ma Ren Run Chang Wan

Beijing Tong Ren Tang Company Limited announced that its subsidiary, Beijing Tong Ren Tang Pharmaceutical Factory, has obtained a Class III product license from Health Canada for its Ma Ren Run Chang Wan. This approval marks the product's official registration in Canada. The company's cumulative research and development investment for this product totals approximately RMB 3.7 million.

The license grants market access for Ma Ren Run Chang Wan, which is indicated for relieving abdominal distension and constipation caused by gastrointestinal heat, and for general bowel lubrication. This approval is a crucial step for the product's potential sale in Canada.

However, the company notes that further administrative approvals, including Canadian Good Manufacturing Practice (GMP) system certification for production facilities, will be required before sales can commence, with some uncertainty surrounding these processes. The company does not anticipate this approval to significantly impact its recent operating performance, but reminds investors of risks associated with overseas sales, including policy changes and market acceptance.